REGENXBIO Inc.RGNXNASDAQ
Loading
R&D Expense Growth Recovery in ProgressRecovering
Percentile Rank56
5Y CAGR-3.1%
Year-over-Year Change
Year-over-year research & development expense growth
5Y CAGR
-3.1%/yr
Long-term compound
Percentile
P56
Within normal range
vs 5Y Ago
0.9x
Contraction
Streak
1 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | 6.26% |
| Q3 2025 | 0.91% |
| Q2 2025 | 4.72% |
| Q1 2025 | 5.37% |
| Q4 2024 | -7.44% |
| Q3 2024 | 21.44% |
| Q2 2024 | -11.54% |
| Q1 2024 | -1.33% |
| Q4 2023 | -11.75% |
| Q3 2023 | -2.84% |
| Q2 2023 | 2.34% |
| Q1 2023 | -6.38% |
| Q4 2022 | -1.28% |
| Q3 2022 | 3.78% |
| Q2 2022 | 9.67% |
| Q1 2022 | 15.94% |
| Q4 2021 | 0.26% |
| Q3 2021 | 4.30% |
| Q2 2021 | 15.51% |
| Q1 2021 | -15.81% |
| Q4 2020 | 7.31% |
| Q3 2020 | 15.37% |
| Q2 2020 | 2.91% |
| Q1 2020 | 9.55% |
| Q4 2019 | -5.28% |
| Q3 2019 | 21.06% |
| Q2 2019 | 16.98% |
| Q1 2019 | 3.59% |
| Q4 2018 | 31.45% |
| Q3 2018 | -13.86% |
| Q2 2018 | 9.90% |
| Q1 2018 | 37.97% |
| Q4 2017 | 13.20% |
| Q3 2017 | -10.05% |
| Q2 2017 | -16.26% |
| Q1 2017 | 3.49% |
| Q4 2016 | 27.86% |
| Q3 2016 | 17.60% |
| Q2 2016 | 72.73% |
| Q1 2016 | 28.49% |